The GPR107 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the GPR107 gene in the human near-haploid HAP1 cell line. This loss-of-function model provides a heterogeneous pool of knockout cells, enabling robust functional genomics studies without single-cell cloning. By eliminating endogenous GPR107 expression, researchers can directly examine its contributions to cellular signaling networks that govern proliferation and survival.
The HAP1 cell line is a near-haploid human chronic myeloid leukemia line, male, derived from KBM-7. Its haploid karyotype minimizes genetic redundancy, facilitating clear genotype-phenotype associations and making it a preferred system for CRISPR-based screens and targeted gene perturbation. HAP1 cells retain intact GPCR signaling cascades and cancer-relevant pathways, rendering them a physiologically appropriate context for studying orphan receptors such as GPR107.
GPR107 is an orphan GPCR that is believed to signal through heterotrimeric G proteins, including GNAQ and GNAS, which activate adenylate cyclase (ADCY) and phospholipase C (PLCB). This leads to the generation of second messengers cAMP and calcium, subsequently engaging downstream effectors such as PRKCA, MAPK1 (ERK2), and AKT1. Consequently, GPR107 modulates both the MAPK/ERK and PI3K/AKT pathways, which are critical for cell growth and survival. Additionally, interaction with ??-arrestin may facilitate receptor desensitization and scaffolding of MAPK components. The absence of a known ligand or upstream regulators underscores the need for knockout models to dissect its signaling mechanisms.
In the HAP1 background, disruption of GPR107 offers a powerful tool to investigate its role in tumorigenesis, particularly in lung cancer and non-small cell lung cancer. The polyclonal nature of the knockout pool captures a spectrum of genetic alterations, reducing clonal artifacts and enabling robust phenotypic analyses such as altered proliferation, migration, and drug responsiveness. This model is especially compatible with pooled CRISPR screens and functional validation experiments, where the haploid genome simplifies data interpretation and enhances the detection of subtle effects.
This product is suitable for a wide range of applications, including cAMP and calcium flux assays to assess GPCR activity, phospho-ERK analysis via western blotting or flow cytometry, and gene expression profiling by RT-qPCR. It can be employed in cell proliferation and colony formation assays to evaluate growth advantages linked to GPR107 signaling. In drug discovery, it serves as a reference for target validation and screening of compounds that modulate downstream pathways. Researchers are encouraged to contact Ascent Research for additional technical information and validation data.
